Hossein Zaeri, Shahriar Omidvar, Nazli Servatian, Serajaddin Arefnia, Nasrin Khademolreza, Hossein Amini, Behnam Taghavi, Mahin Hashemipour, Peyman Eshraghi, Mahmoud Ghasemi, Robabeh Ghergherehchi, Elham Maleki, Hossein Moravej, Shahab Noorian, Fahimeh Soheilipour, Setila Dalili, Hosseinali Kharazmi, Abdollah Didban, Aliasghar Akhlaghi, Sina Ghaznavi, Majid Shahbazi
OBJECTIVES: This study is designed in order to compare the efficacy and safety of recombinant human growth hormone (rhGH) with the reference brand. METHODS: According to the inclusion criteria, 85 people in 13 Iranian centers were randomly selected to receive biosimilar Somatropin (Somatin®) (44 people) and reference Somatropin (Norditropin®) (41 people) at a dose of 35 µg/kg/d, seven days/week for 12 months. The primary outcomes included height velocity (HV) was measured during 12 months of treatment...
April 29, 2024: Expert Opinion on Drug Safety